View ValuationSimulations Plus 将来の成長Future 基準チェック /26Simulations Plusは、12.1%と9.6%でそれぞれ年率12.1%で利益と収益が成長すると予測される一方、EPSはgrowで6.4%年率。主要情報12.1%収益成長率6.43%EPS成長率Healthcare Services 収益成長20.0%収益成長率9.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Jul 2026今後の成長に関する最新情報お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.すべての更新を表示Recent updatesReported Earnings • 21hThird quarter 2026 earnings released: EPS: US$0.18 (vs US$3.35 loss in 3Q 2025)Third quarter 2026 results: EPS: US$0.18 (up from US$3.35 loss in 3Q 2025). Revenue: US$21.9m (up 7.5% from 3Q 2025). Net income: US$3.58m (up US$70.9m from 3Q 2025). Profit margin: 16% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jun 29+ 1 more updateSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth-Defensive IndexSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth-Defensive Indexお知らせ • Jun 18Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million.Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million on June 16, 2026. Under the terms of the agreement, Simulations Plus common stockholders will receive $18.5 per share, representing a premium of 26% to Simulations Plus’ 60-day volume-weighted average price as of June 15, 2026. The transaction will be financed through a combination of committed equity and debt financing through funds affiliated with Altaris. Upon completion of the transaction, Simulations Plus’ headquarters is expected to remain in Research Triangle Park, North Carolina. Upon closing, Simulations Plus will become a privately held subsidiary of Altaris and its common stock will no longer be traded on the Nasdaq Stock Exchange. Additionally, Altaris anticipates Simulations Plus, Inc. will be combined with Chemical Computing Group. The transaction, which was unanimously approved by the Simulations Plus Board of Directors, is subject to customary closing conditions including the receipt of approval of the Simulations Plus stockholders, required regulatory, and other similar approvals and closing conditions. The transaction is currently expected to close in the calendar fourth quarter of 2026. In connection with the execution of the merger agreement, Simulations Plus cofounder and director Dr. Walter Woltosz has entered into a voting and support agreement with Altaris pursuant to which he has agreed to vote all of the shares beneficially owned by him in favor of the transaction. Truist Securities, Inc. acted as financial advisor for Altaris, LLC. J.P. Morgan Securities LLC acted as financial advisor for Altaris, LLC. Morgan Stanley & Co. LLC acted as financial advisor for Simulations Plus, Inc. Procopio Cory Hargreaves & Savitch LLP acted as legal advisor for Simulations Plus, Inc. Kirkland & Ellis LLP acted as legal advisor for Altaris, LLC. Bass, Berry & Sims PLC acted as legal advisor for Altaris.お知らせ • Jun 16Simulations Plus, Inc. to Report Q3, 2026 Results on Jul 09, 2026Simulations Plus, Inc. announced that they will report Q3, 2026 results on Jul 09, 2026Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Director Sharlene Evans was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.お知らせ • Mar 27Simulations Plus, Inc. to Report Q2, 2026 Results on Apr 09, 2026Simulations Plus, Inc. announced that they will report Q2, 2026 results After-Market on Apr 09, 2026お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.お知らせ • Dec 30Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026.業績と収益の成長予測DB:SD3 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数8/31/202896N/A13N/A18/31/202786108N/A58/31/20268299N/A55/31/20268282225N/A2/28/202681-632124N/A11/30/202579-642024N/A8/31/202579-651418N/A5/31/202580-631114N/A2/28/2025797812N/A11/30/2024748812N/A8/31/20247010913N/A5/31/202467101015N/A2/29/202465111318N/A11/30/202362111317N/A8/31/202360101822N/A5/31/202356102227N/A2/28/202354101822N/A11/30/202253111519N/A8/31/202254121418N/A5/31/202252121418N/A2/28/202250121419N/A11/30/202148101217N/A8/31/202146101519N/A5/31/202146121216N/A2/28/202146111014N/A11/30/202043101114N/A8/31/2020429811N/A5/31/202040969N/A2/29/2020389N/A10N/A11/30/2019369N/A12N/A8/31/2019349N/A12N/A5/31/2019338N/A12N/A2/28/2019317N/A11N/A11/30/2018309N/A9N/A8/31/2018309N/A9N/A5/31/2018299N/A8N/A2/28/2018278N/A9N/A11/30/2017266N/A8N/A8/31/2017246N/A7N/A5/31/2017225N/A7N/A2/28/2017215N/A6N/A11/30/2016215N/A8N/A8/31/2016205N/A5N/A5/31/2016205N/A6N/A2/29/2016205N/A6N/A11/30/2015194N/A7N/A8/31/2015184N/A7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SD3の予測収益成長率 (年間12.1% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: SD3の収益 ( 12.1% ) German市場 ( 16.9% ) よりも低い成長が予測されています。高成長収益: SD3の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SD3の収益 ( 9.6% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: SD3の収益 ( 9.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SD3の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 23:49終値2026/07/10 00:00収益2026/05/31年間収益2025/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Simulations Plus, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関David LarsenBTIGDane LeoneCGS InternationalConstantine DavidesCitizens JMP Securities, LLC7 その他のアナリストを表示
お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.
Reported Earnings • 21hThird quarter 2026 earnings released: EPS: US$0.18 (vs US$3.35 loss in 3Q 2025)Third quarter 2026 results: EPS: US$0.18 (up from US$3.35 loss in 3Q 2025). Revenue: US$21.9m (up 7.5% from 3Q 2025). Net income: US$3.58m (up US$70.9m from 3Q 2025). Profit margin: 16% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jun 29+ 1 more updateSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth-Defensive IndexSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth-Defensive Index
お知らせ • Jun 18Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million.Altaris, LLC entered into a definitive agreement to acquire Simulations Plus, Inc. (NasdaqGS:SLP) from Walter Woltosz and others for approximately $370 million on June 16, 2026. Under the terms of the agreement, Simulations Plus common stockholders will receive $18.5 per share, representing a premium of 26% to Simulations Plus’ 60-day volume-weighted average price as of June 15, 2026. The transaction will be financed through a combination of committed equity and debt financing through funds affiliated with Altaris. Upon completion of the transaction, Simulations Plus’ headquarters is expected to remain in Research Triangle Park, North Carolina. Upon closing, Simulations Plus will become a privately held subsidiary of Altaris and its common stock will no longer be traded on the Nasdaq Stock Exchange. Additionally, Altaris anticipates Simulations Plus, Inc. will be combined with Chemical Computing Group. The transaction, which was unanimously approved by the Simulations Plus Board of Directors, is subject to customary closing conditions including the receipt of approval of the Simulations Plus stockholders, required regulatory, and other similar approvals and closing conditions. The transaction is currently expected to close in the calendar fourth quarter of 2026. In connection with the execution of the merger agreement, Simulations Plus cofounder and director Dr. Walter Woltosz has entered into a voting and support agreement with Altaris pursuant to which he has agreed to vote all of the shares beneficially owned by him in favor of the transaction. Truist Securities, Inc. acted as financial advisor for Altaris, LLC. J.P. Morgan Securities LLC acted as financial advisor for Altaris, LLC. Morgan Stanley & Co. LLC acted as financial advisor for Simulations Plus, Inc. Procopio Cory Hargreaves & Savitch LLP acted as legal advisor for Simulations Plus, Inc. Kirkland & Ellis LLP acted as legal advisor for Altaris, LLC. Bass, Berry & Sims PLC acted as legal advisor for Altaris.
お知らせ • Jun 16Simulations Plus, Inc. to Report Q3, 2026 Results on Jul 09, 2026Simulations Plus, Inc. announced that they will report Q3, 2026 results on Jul 09, 2026
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Director Sharlene Evans was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.
お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.
お知らせ • Mar 27Simulations Plus, Inc. to Report Q2, 2026 Results on Apr 09, 2026Simulations Plus, Inc. announced that they will report Q2, 2026 results After-Market on Apr 09, 2026
お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.
お知らせ • Dec 30Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026.